ARE SEXUAL SIDE EFFECTS OF PROLACTIN-RAISING ANTIPSYCHOTICSREDUCIBLE TO SERUM PROLACTIN?

2008 ◽  
Vol 102 (1-3) ◽  
pp. 239
Author(s):  
Henderikus Knegtering ◽  
Durk Wiersma ◽  
Stynke Castelein ◽  
Richard Bruggeman ◽  
Jim van Os
2013 ◽  
Vol 37 (5) ◽  
pp. 164-166 ◽  
Author(s):  
Abraham M. Nussbaum ◽  
T. Scott Stroup

Aims and methodTo review the evidence for the use of paliperidone palmitate for people with schizophrenia and schizophrenia-like illnesses. We searched the Cochrane Schizophrenia Group Specialised Register and contacted the manufacturer of paliperidone palmitate, the US Food and Drug Administration, and the authors of papers that reported study results.ResultsBased on the evidence from five short-term, placebo-controlled studies, paliperidone palmitate is efficacious as an antipsychotic. Its adverse effects are similar to those of the closely related compounds paliperidone and risperidone. Extrapyramidal side-effects, weight gain and tachycardia are more common with paliperidone palmitate than placebo. Paliperidone palmitate was associated with substantial increases in serum prolactin but not with increased sexual side-effects in these studies. In two studies paliperidone palmitate was similar to depot risperidone.Clinical implicationsPaliperidone palmitate is an effective antipsychotic whose optimal dose appears to be between 39 and 234 mg every 4 weeks. We have no data assessing its long-term effectiveness or comparing it with any long-acting injected antipsychotic other than depot risperidone.


2008 ◽  
Vol 33 (6) ◽  
pp. 711-717 ◽  
Author(s):  
Henderikus Knegtering ◽  
Rob van den Bosch ◽  
Stynke Castelein ◽  
Richard Bruggeman ◽  
Sjoerd Sytema ◽  
...  

BJPsych Open ◽  
2015 ◽  
Vol 1 (2) ◽  
pp. 172-177 ◽  
Author(s):  
G. Raghuthaman ◽  
R. Venkateswaran ◽  
R. Krishnadas

BackgroundHyperprolactinaemia is a troublesome side-effect of treatment with antipsychotics.AimsThis double-blind, placebo-controlled study aimed at examining the effect of adjunctive treatment with 10 mg aripiprazole on prolactin levels and sexual side-effects in patients with schizophrenia symptomatically maintained on risperidone.MethodThirty patients taking risperidone were enrolled into the trial (CTRI/2012/11/003114). Aripiprazole was administered at a fixed daily dose of 10 mg/day for 8 weeks. Serum prolactin was measured at baseline and at 8 weeks. Hyperprolactinaemia-related problems, psychopathology and side-effects were evaluated every 2 weeks.ResultsProlactin levels decreased by 58% in the aripiprazole group compared with an increase by 22% in the placebo group. Prolactin levels normalised in 46% of patients in the aripiprazole group (number needed to treat, NNT=2). Aripiprazole improved erectile dysfunction in five out of six patients. There were no significant differences in change in psychopathology or side-effects between groups.ConclusionsAdjunctive aripiprazole reduced prolactin levels in those treated with risperidone, with no effect on psychopathology and extrapyramidal symptoms. This is a potential treatment for hyperprolactinaemia observed during treatment with second-generation antipsychotics.


2019 ◽  
Vol 25 (41) ◽  
pp. 5698-5711 ◽  
Author(s):  
Leonardo F. Fontenelle ◽  
Maiara Zeni-Graiff ◽  
Julliana N. Quintas ◽  
Murat Yücel

Many of the currently available treatments for obsessive-compulsive and related disorders (OCRDs) such as pharmacotherapy augmentation strategies, partial hospitalization programs, deep brain stimulation, and neurosurgery are efficacious for individuals suffering from more severe forms of these conditions. Unfortunately, the application of these treatments in milder forms of illness and subclinical samples, which affect a substantial portion of the population, is not justifiable by their costs (e.g. cognitivebehavioral therapy) and/or potential for side effects (serotonin-reuptake inhibitors associated sexual side effects). As such, there is an urgent need to develop simple yet effective treatments, such as modifiable lifestyle interventions, that can be employed on a broader scale. Here, we review the current state of evidence that supports or refutes the efficacy of lifestyle approaches for OCRDs. We focus on dimensions of lifestyle that are deemed important for cardiovascular diseases; namely, physical activity, stress, sleep, diet and eating behaviors, alcohol consumption, and smoking. Despite the relative scarcity of welldesigned randomized controlled trials targeting unhealthy life styles in OCRDs, we found meditation-based therapies and interventions focusing on eliminating sedentarism to be promising approaches. In the future, these strategies may represent valid alternative for subjects with subthreshold symptoms or at risk for OCRDs or other “compulsive” disorders.


1997 ◽  
Vol 61 (4) ◽  
pp. 478-487 ◽  
Author(s):  
Jack G. Modell ◽  
Charles R. Katholi ◽  
Judith D. Modell ◽  
R. Lawrence DePalma

1989 ◽  
Vol 32 (1) ◽  
pp. 223-227 ◽  
Author(s):  
M. De Gasparo ◽  
S.E. Whitebread ◽  
G. Preiswerk ◽  
X. Jeunemaître ◽  
P. Corvol ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document